Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT1-receptor antagonism

British Journal of Pharmacology

Volumn 131, Issue 1, 2000, Pages 138-144

  Weidenbach, R ^a   Schulz, R ^a   Gres, P ^a   Behrends, M ^a   Post, H ^a   Heusch, G ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Bradykinin; Candesartan; Myocardial ischaemia; Ramiprilat; Reperfusion; Swine

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; RAMIPRILAT;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEMODYNAMICS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SWINE;

EID: 0033832381     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703544     Document Type: Article

References (59)

1. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
2. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
3. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure
4. Ramiprilat increases bradykinin outflow from isolated hearts of rat
5. Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion
6. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells
7. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme
8. Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study
9. 1 receptor antagonist candesartan
10. Attenuation of myocardial stunning by the ACE-inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins, but not nitric oxide
11. GISSI-3: Effects of lisinopril and transdermal glyceril trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
12. Myocardial neutrophil accumulation during reperfusion after reversible or irreversible ischemic injury
13. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts
14. Reduction of myocardial infarct size in rabbits by ramiprilat: Reversal by the bradykinin antagonist HOE 140
15. + activity in swine
16. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction
17. 2-receptor activation, bradykinin and prostaglandins in pigs
18. 1 receptor blockade in experimental myocardial ischemia/reperfusion
19. 1 receptor blockade in experimental myocardial ischemia/reperfusion
20. Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs
21. The mechanism of the tetrazolium reaction in identifying experimental myocardial infarction
22. Absence of hemodynamic deterioration in the presence of amlodipine following experimental myocardial infarction
23. 1 receptor inhibition, and combination therapy with pacing induced heart failure: Effects on left ventricular performance and regional blood flow patterns
24. The effects of a critical stenosis on myocardial blood flow, ventricular function, and infarct size after coronary reperfusion
25. Interactions among ACE, kinins and NO
26. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors
27. Vasodilator reserve in collateral-dependent myocardium as measured by positron emission tomography
28. Comparison of candesartan, enalapril, and their combination in congestive heart failure
29. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats
30. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
31. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE)
32. No involvement of endogenous nitric oxide in classical ischemic preconditioning in swine
33. Impact of resting and ischemic blood flow on infarct probability in ischemic preconditioning - A new approach to infarct size-blood flow data by logistic regression
34. Effects of candesartan cilexetil in patients with systemic hypertension
35. Animal models for protecting ischemic myocardium: Results of the NHLBI cooperative study. Comparison of unconscious and conscious dog models
36. Reduced arachidonate metabolism in ATP-depleted myocardial cells occurs early in cell injury
37. Effect of coronary collateral circulation on myocardial ischemia and ventricular dysfunction
38. The collateral circulation of the heart
39. Ischemic preconditioning reduces infarct size in swine myocardium
40. Consequences of regional inotropic stimulation of ischemic myocardium on regional myocardial blood flow and function in anesthetized swine
41. Ischemic preconditioning in pigs: A graded phenomenon. Its relation to adenosine and bradykinin
42. Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart
43. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation
44. Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury
45. The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion
46. Cordat II: A new program for data acquisition and on-line calculation of hemodynamic and regional myocardial dimension parameters
47. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure I. Effects on left ventricular performance and neurohormonal systems
48. Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Intravascular two-dimensional and doppler ultrasound studies
49. Regional myocardial function during acute coronary artery occlusion and its modification by pharmacological agents in the dog
50. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation
51. Effects of calcium channel blocker on responses of blood flow, function, arrhythmias, and extent of infarction following reperfusion in conscious baboons
52. 2 receptors
53. Role of bradykinin in myocardial preconditioning
54. A quantitative study of the anatomy and distribution of coronary arteries in swine in comparison with other animals and man
55. Coronary collateral circulation in the pig: Correlation of collateral flow with coronary bed size
56. Effects of the K-ATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs
57. Ischaemic preconditioning: Present position and future directions
58. Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway
59. Effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury: An overview